Physician profile
Gene O Devane
NPI 1518198639
$1,610.79
in general payments reported to CMS, 2019-2025
22 companies · $970 in 2025
The $970 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $269 · 2024: $372 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $197.74 | 2024-2025 | Ortholoc 2 Lapifuse, Actishield, Smart Toe |
| Tactile Systems Technology INC | $178.83 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Access Pro Medical, LLC | $176.74 | 2025 | Matriderm |
| Kerecis Limited | $160.97 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Smith+Nephew, INC. | $125.17 | 2023-2024 | Grafix Pl, Stravix Pl, Collagenase Santyl |
| Linvatec Corporation | $113.93 | 2025 | Hercules Suture Anchor System, Quantum, Ibs |
| Paratek Pharmaceuticals, INC. | $97.64 | 2023-2025 | Nuzyra |
| Azurity Pharmaceuticals, INC. | $75.85 | 2023-2025 | Horizant, Horizant |
| Vertex Pharmaceuticals Incorporated | $66.65 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.06 | 2025 | Caplyta |
| Orthofix Medical, INC. | $44.48 | 2023-2025 | Physio-Stim |
| Exact Sciences Corporation | $41.11 | 2025 | The Cologuard Plus Collection Kit |
| Depuy Synthes Sales INC. | $34.02 | 2023 | Dynaforce, Na |
| Urgo Medical North America, LLC | $33.17 | 2024-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgoclean Ag |
| Organogenesis INC. | $31.52 | 2023-2024 | Puraply |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $31.47 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Integra Lifesciences Corporation | $30.72 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Bioventus LLC | $26.17 | 2023 | |
| Averitas Pharma INC. | $24.49 | 2024 | Qutenza |
| Pacira Pharmaceuticals Incorporated | $22.89 | 2024 | Exparel, Iovera |
| Abbvie INC. | $21.53 | 2024 | |
| Tela Bio, INC. | $19.64 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Devane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.